Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Sho Aoki
Potent Antitumor Effect of Combination Therapy With Sub‑optimal Doses of Akt Inhibitors and Pomalidomide Plus Dexamethasone in Multiple Myeloma
Oncology Letters
Cancer Research
Oncology
Aluminium Composite Materials Possessing Magnetic Properties Produced by MA-SPS Process
Funtai Oyobi Fummatsu Yakin/Journal of the Japan Society of Powder and Powder Metallurgy
Alloys
Industrial
Mechanical Engineering
Metals
Materials Chemistry
Manufacturing Engineering
Related publications
Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Orphan Designation: Pomalidomide, Treatment of Multiple Myeloma
Case Medical Research
Pomalidomide Plus Low-Dose Dexamethasone Versus High-Dose Dexamethasone Alone for Patients With Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-Label, Phase 3 Trial
The Lancet Oncology
Oncology
STK405759 as a Combination Therapy With Bortezomib or Dexamethasone, in in Vitro and in Vivo Multiple Myeloma Models
Oncotarget
Oncology
Generation of Potent Antitumor CTL From Patients With Multiple Myeloma Directed Against HM1.24
Clinical Cancer Research
Cancer Research
Oncology
Response to Salvage Therapies and Outcome in Patients With Multiple Myeloma Relapsing After Pomalidomide Therapy
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Isatuximab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: IKEMA Phase III Study Design
Future Oncology
Medicine
Cancer Research
Oncology
Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma
Hematology
Hematology
Review New Drugs in Multiple Myeloma – Role of Carfilzomib and Pomalidomide
Wspolczesna Onkologia
Oncology
Radiology
Nuclear Medicine
Imaging
